MarketLens
Sign Up

Why Did Raymond James Downgrade BridgeBio Pharma

4 months ago
SHARE THIS ON:

Why Did Raymond James Downgrade BridgeBio Pharma

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•2 months ago

BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder

BridgeBio Pharma launched a secondary offering of 5M shares by KKR Genetic Disorder L.P., with no proceeds to the company. The sale could pressure shares near-term due to added supply.
Stock News•3 months ago

BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment

BridgeBio Oncology Therapeutics fell >30% since prior coverage, but remains a Buy with BB-8520 showing 65% ORR and 100% DCR in KRAS G12C NSCLC. Mature data readouts due 2H26 could be key catalysts.
Stock News•3 months ago

BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?

BridgeBio Pharma (BBIO) rose 15.1% on above-average volume, but recent earnings estimate revisions suggest limited further upside.

Breaking News

View All →

Top Headlines

View More →
Stock News•31 minutes ago

Tesla's stock falls as Elon Musk leaves investors wanting more

Stock News•53 minutes ago

Meta's stock rises as investors glimpse an opportunity that could dwarf the ad business

Stock News•58 minutes ago

Q3 Earnings Beats for Meta, Tesla, IBM and T.I.

Stock News•59 minutes ago

Meta Q3: From Facebook To Muse, Strong Growth Makes This A Strong Buy

Stock News•1 hour ago

2 Healthcare Stocks to Buy After Crushing Q3 Earnings Expectations: ELV & ISRG